DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION				
DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION			
One Montvale Avenue	1/31/2018-2/8/2018*			
Stoneham, MA 02180	FEI NUMBER			
(781)587-7500 Fax: (781)587-7556	3014174643			
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED	•			
Bret Snow, Regional Director of Pharmacy				
FIRM NAME	STREET ADDRESS			
New England Life Care, Inc.	4 Constitution Way Suite J			
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED			
Woburn, MA 01801-1042	Producer of Sterile Drug Products			

This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.

### DURING AN INSPECTION OF YOUR FIRM I OBSERVED:

### **OBSERVATION 1**

Personnel moved rapidly in the vicinity of open sterile units and instruments, which disrupted the airflow and increased the risk of bringing lesser quality air into the ISO 5 classified aseptic processing area.

# Specifically,

I observed the following:

- On January 31, 2018, Pharmacy Technician (b) (6) had prepared materials and supplies for aseptic processing and filling activities in the unclassified Pharmacy area with her bare hands after sanitizing the materials and supplies with (b) (4)
- On January 31, 2018, Pharmacy Technician(b) (6) was sterile processing TPN products in Hood RX# (b) (6) I observed that (b) (6) consistently put the top of her head (exposing the skin from her neck and face) into the hood along with parts of her shoulders. I also noted on February 1, 2018, an instance in which(b) (6) left the ISO 5 hood for supplies in the ISO 8 area and upon her return to the ISO 5 (b) (6) neglected to change and/or sanitize her gloves prior to entry into the ISO 5 Hood. (b) (6) had processed RX#'s (b) (6) (b) (6)

SEE REVERSE OF THIS PAGE  EMPLOYEE(S) SIGNATURE Robert J Martin, Investigator	Robert J Martin Investigation Signed By Robert J Martin -S Daile Signed 02-06-2018 10 12 16	2/8/2018
---	---	----------

FORM FDA 483 (09/08) PREVIOUS EDITION OBSOLETE INSPECTIONAL OBSERVATIONS PAGE 1 OF 5 PAGES

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION					
DISTRICT ADDRESS AND PHON	E NUMBER		DATE(S) OF INSE	PECTION 018-2/8/2018*	
Stoneham, MA	02180 FEI NUMBER				
(781) 587-7500	Fax: (781) 587-7556		3014174	1043	
NAME AND TITLE OF INDIVIDUA	L TO WHOM REPORT ISSUED				
7/	egional Director of Pharmacy				
New England I	life Care, Inc.	STREET ADDRESS  4 Constitution Way Suite J			
CITY, STATE, ZIP CODE, COUNT Woburn, MA 01		TYPE ESTABLISHMENT INSPECTED Producer of Sterile Drug Products			
On January 31, 2018, Pharmacy Technician(b) (6) was sterile processing and filling Imipenem-Cilastatin 500mg/100mL NS, Cefepime 2000mg/20mL SWFI, Iron Sucrose 20mg/10mL NS and Ampicillin 12g/620mL NS (RX#'s(b) (6)  (b) (6) in Hood (b) (4) I observed (b) (6) consistently put the top of his head (exposing the skin from his neck and face) into the hood along with parts of his shoulders. Also noted was whe (b) (6) would reach for supplies located on the top of the hood his chest would routinely break the plane of the hood (b) (6) Pharmacy 2, 2018, I noted that while(b) (6) was processing TPN products within Hood (b) (6) (6) non-sterile sleeves came in contact with the aseptic connection for the (b) (4) machine.  On January 31, 2018, Pharmacy Techniciar (b) (6) was sterile processing TPN products in Hood (exposing the skin from her neck and face) into hood along with parts of her shoulders.  OBSERVATION 2					
OBSERVATION 2 You had inadequate HEPA filter coverage and airflow over the area to which sterile product was exposed.  Specifically,  The requalifications of the (b) (4) ISO 5 Laminar Flow Hoods (Models (b) (4) (b) (4) were inadequate in that the static and dynamic smokes studies conducted did not demonstrate the actual setup and aseptic operations within the Laminar Flow Hoods as used by the firm during routine processing operations. For example, the August 2017 requalification of these hoods indicates that static and dynamic smoke studies were conducted; however, there was inadequate documentation of said activities within the report. Furthermore, Hood so routinely used for TPN processing operations which contains a (b) (4) unit with numerous accessories which comprise					
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Robert J Martin, Investigate	r		Robert J Martin Investigator Signed by Robert J. Martin -S Date Signed 02-09-2016 10 12 16	DATE ISSUED 2/8/2018

INSPECTIONAL OBSERVATIONS

PAGE 2 OF 5 PAGES

FORM FDA 483 (09/08)

PREVIOUS EDITION OBSOLETE

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION				
DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION			
One Montvale Avenue	1/31/2018-2/8/2018*			
Stoneham, MA 02180	FEI NUMBER			
(781)587-7500 Fax: (781)587-7556	3014174643			
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED				
Bret Snow, Regional Director of Pharmacy				
FIRM NAME	STREET ADDRESS			
New England Life Care, Inc.	4 Constitution Way Suite J			
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED			
Woburn, MA 01801-1042	Producer of Sterile Drug Products			

approximately 60 of the hood's capacity and without adequately documenting the airflow smoke pattern it cannot be determined that this setup would have an effect on the unidirectional airflow within the hood to ensure that the sterility of the product is maintained.

# **OBSERVATION 3**

You produced beta-lactam drugs without providing adequate cleaning of utensils to prevent crosscontamination.

Specifically,

The firm's cleanroom design and operational procedures do not provide adequate segregation of Beta-Lactam antibiotic products from general drugs produced. Beta-Lactam antibiotics are processed in the same laminar flow hoods (Hoods (b) (4) as other general drug products separated only by a wipe down with(b) (4) . For example:

- On January 31, 2018, Pharmacy Technician (b) (6) processed the following products in Hood (b) (4) 10:00am - Imipenem-Cilastatin 500mg in 100mL NS (RX#(b) (6) Cefepime 2000mg in 20mL SWFI (RX# (b) (6) , 12:30pm – Iron Sucrose 20mg in 10mL NS (RX# (b) (6) and 1:30pm – Ampicillin 12g in 620mL NS (RX# (b) (6)
- On February 1, 2018, Pharmacy Technician (b) (6) processed the following products in Hood 10:30am Ceftriaxone 2000mg in 20mL SWFI (RX# (b) (6) , 11:00am – Ceftriaxone 2g in 20mL SWFI (RX# (b) (6) and 3:00pm – Methadone 50mmg in 100mL NS (RX# (b) (6)

SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Robert J Martin, Inv	estigator	Robert J Martin Investigator Signed By Robert J. Martin -S Date Signed 02-08-2018 10 12 16	DATE ISSUED 2/8/2018
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL OBSERVATION	ONS	PAGE 3 OF 5 PAGES

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION				
DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION			
One Montvale Avenue	1/31/2018-2/8/2018*			
Stoneham, MA 02180	FEI NUMBER			
(781)587-7500 Fax: (781)587-7556	3014174643			
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED	•			
Bret Snow, Regional Director of Pharmacy				
FIRM NAME	STREET ADDRESS			
New England Life Care, Inc.	4 Constitution Way Suite J			
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED			
Woburn, MA 01801-1042	Producer of Sterile Drug Products			

Furthermore, the firm does not have a specific process to decontaminate any Beta-Lactam product spillage that may occur within the Laminar Flow Hoods during production or filling operations.

## **OBSERVATION 4**

Non-microbial contamination was observed in your production area.

Specifically,

On January 31, 2018, I observed several ceiling tiles within the Pharmacy that had what appeared to be water stains and/or had stains that had been painted over. Also noted was an unknown material splashed on the exterior side to the door leading into the ISO 8 Gowning Room.

## OBSERVATION 5

Disinfecting agents and cleaning pads and cleaning wipes used in the ISO 5 classified aseptic processing areas were not sterile.

Specifically,

The firm uses non-sterile disinfectants for (b) (4) sanitization of the interior surfaces of the ISO 5 Hoods (b) (4). For example, technicians will sanitize and disinfect the ISO 5 Hoods on a(b) (4) basis using (b) (4) Brand (b) (4) Disinfectant Cleaner which is non-sterile. These ISO 5 Hoods are used for sterile compounding and filling operations.

OF THIS PAGE  Robert J Martin Investigation X Signed 02-48-2018 10 12 16		SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Robert J Martin,	Investigator	Investigator	DATE ISSUED 2/8/2018
--	--	-----------------------------	--	--------------	--------------	----------------------

FORM FDA 483 (09/08) PREVIOUS EDITION OBSOLETE INSPECTIONAL OBSERVATIONS PAGE 4 OF 5 PAGES

FOOD AND DRI	LTH AND HUMAN SERVI JG ADMINISTRATION		
One Montvale Avenue	50.50	2018-2/8/2018*	
Stoneham, MA 02180	FEI NUMBER	Control of the Contro	
(781)587-7500 Fax: (781)587-7556	30141	14643	
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED	le .		
Bret Snow, Regional Director of Pharmacy			
FIRM NAME	STREET ADDRESS	TT TO COMPANY OF THE PARTY OF T	
New England Life Care, Inc. CITY, STATE, ZIP CODE, COUNTRY	4 Constitution  TYPE ESTABLISHMENT INSPECTED		
Woburn, MA 01801-1042	AND A TRUBBLE DESIGNATION AND ADDRESS OF STREET	erile Drug Produ	icts
*DATES OF INSPECTION 1/31/2018(Wed), 2/01/2018(Thu), 2/02/2018(Fri),	2/05/2018(Mon), 2/	708/2018(Thu)	
SEE REVERSE OF THIS PAGE  EMPLOYEE(S) SIGNATURE Robert J Martin, Investigat	or	Robert J Martin Investigator Signed 6y Robert J, Martin -S Daile Signed 02-96-2018 10 12 16	DATE ISSUED 2/8/2018
FORM FDA 483 (09/08) PREVIOUS EDITION OBSOLETE IN	SPECTIONAL OBSERVA	ΠΟΝS	PAGE 5 OF 5 PAGES